Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

In a regulatory filing, Tempus AI (TEM) disclosed that COO Ryan Fukushima sold 20,000 shares of the company’s stock. The ...

Chief Operating Officer Ryan Fukushima recently sold a significant portion of his holdings in the company, according to a ...

We recently compiled a list of the 10 Firms Shine Amid Market Slump. In this article, we are going to take a look at where ...

Tempus AI's innovative products are transforming the healthcare industry, with a focus on oncology and large market ...

Let's explore the Tempus AI stock price and whether it is a good company to buy and hold despite its overvaluation.

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

In a regulatory filing, Tempus AI (TEM) disclosed that COO Ryan Fukushima sold 20,000 shares of the company’s stock. The stock was sold at an average price of $62.50, for a total value of $1.2M.

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...